{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"58.0","spread":"58.0","value":"369.3"},{"groupId":"OG001","lowerLimit":"136.1","spread":"136.1","value":"179.4"},{"groupId":"OG002","lowerLimit":"25.0","spread":"25.0","value":"348.7"},{"groupId":"OG003","lowerLimit":"20.6","spread":"20.6","value":"323.3"}]}],"title":"Eribulin"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"165.9","spread":"165.9","value":"538.8"},{"groupId":"OG001","lowerLimit":"19.1","spread":"19.1","value":"399.5"},{"groupId":"OG002","lowerLimit":"39.8","spread":"39.8","value":"1168.1"},{"groupId":"OG003","lowerLimit":"39.5","spread":"39.5","value":"1555.4"}]}],"title":"Irinotecan"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.4","spread":"9.4","value":"6.518"},{"groupId":"OG001","lowerLimit":"39.7","spread":"39.7","value":"17.170"},{"groupId":"OG002","lowerLimit":"51.6","spread":"51.6","value":"25.409"},{"groupId":"OG003","lowerLimit":"74.3","spread":"74.3","value":"18.614"}]}],"title":"Active Metabolite SN-38"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"}],"units":"Participants"}],"dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received eribulin mesilate 1.4 mg/m\\^2 intravenous infusion on Days 1 and 8 and irinotecan hydrochloride 20 mg/m\\^2, intravenous infusion on Days 1 to 5 in every 21 days treatment cycle until disease progression, development of intolerable toxicity or withdrawal of consent.","id":"OG000","title":"Phase 1: Schedule A, Eribulin Mesilate 1.4 mg/m^2 + Irinotecan 20 mg/m^2"},{"description":"Participants received eribulin mesilate 1.4 mg/m\\^2, intravenous infusion on Days 1 and 8 and irinotecan hydrochloride 40 mg/m\\^2, intravenous infusion on Days 1 to 5 in every 21 days treatment cycle until disease progression, development of intolerable toxicity or withdrawal of consent.","id":"OG001","title":"Phase 1: Schedule A, Eribulin Mesilate 1.4 mg/m^2 + Irinotecan 40 mg/m^2"},{"description":"Participants received eribulin mesilate 1.4 mg/m\\^2 and irinotecan hydrochloride 100 mg/m\\^2 intravenous infusion on Days 1 and 8 in every 21 days treatment cycle until disease progression, development of intolerable toxicity or withdrawal of consent.","id":"OG002","title":"Phase 1: Schedule B, Eribulin Mesilate 1.4 mg/m^2 + Irinotecan 100 mg/m^2"},{"description":"Participants received eribulin mesilate 1.4 mg/m\\^2 and irinotecan hydrochloride 125 mg/m\\^2 intravenous infusion on Days 1 and 8 in every 21 days treatment cycle until disease progression, development of intolerable toxicity or withdrawal of consent.","id":"OG003","title":"Phase 1: Schedule B, Eribulin Mesilate 1.4 mg/m^2 + Irinotecan 125 mg/m^2"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK analysis set included participants who had documented dosing history and at least one post-dosing quantifiable drug concentration.","reportingStatus":"POSTED","timeFrame":"For eribulin, Cycle 1 Day 1: 0-120 hours post-eribulin infusion; For irinotecan and its metabolite, Cycle 1 Day 1: 0-24 hours post-irinotecan infusion (cycle length=21 days)","title":"Phase 1, Cmax: Maximum Observed Plasma Concentration of Eribulin, Irinotecan and Its Active Metabolite SN-38","type":"SECONDARY","unitOfMeasure":"nanogram/milliliter (ng/mL)"}